SCHEMBL10179565

SCHEMBL10179565

COc1ccc(CC(=O)c2ccccc2)c(NC(=O)O)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.51
NPC1 O15118 7/20 0.51
RAB9A P51151 7/20 0.51
MEN1 O00255 6/20 0.51
MAPT P10636 2/20 0.51
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.51
ALOX12 P18054 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MAPK1 P28482 1/20 0.46
POLB P06746 1/20 0.45
EPHX2 P34913 1/20 0.45
THRB P10828 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NLRP3 Q96P20 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4568012 0.85 KMT2A (0.45) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL10179873 0.84 MCHR1 (0.42) KMT2ARAB9AMEN1MAPTALDH1A1
SCHEMBL7978840 0.82 KMT2A (0.49) KMT2AMEN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL6849659 0.80 L3MBTL1 (0.58) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL6202473 0.80 POLB (0.61) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL17220696 0.79 POLB (0.47) KMT2AMAPTSMN1; SMN2ALDH1A1TP53
SCHEMBL15998608 0.78 NPC1 (0.53) KMT2ANPC1RAB9AMEN1LMNA
SCHEMBL6118223 0.78 NPC1 (0.52) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL6117524 0.78 NPC1 (0.50) KMT2ANPC1RAB9AMEN1MAPT
SCHEMBL6116601 0.78 NPC1 (0.50) KMT2ANPC1RAB9AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2474530-B1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL (JP) 2014-09-03 EP disclosed
US-8815903-B2 Indole derivative and pharmacologically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-08-26 US disclosed
EP-2669272-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT OF SAME Kissei Pharmaceutical Co., Ltd. (JP) 2013-12-04 EP disclosed
US-20130317065-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL COMPANY, LIMITED (JP) 2013-11-28 US disclosed
EP-2474530-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2012-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317065-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, LTB4R KMT2A 1898/4885NPC1 1715/4885RAB9A 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.